Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children (HIT-REZ-2005)
Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents
Sponsor: University Hospital, Bonn
Listed as NCT00749723, this PHASE2/PHASE3 trial focuses on Ependymomas and Medulloblastomas and remains completed. Sponsored by University Hospital, Bonn, it has been updated 8 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
Status: Unknown Status → Completed
▶ Show 3 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Unknown Status PHASE2_PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
First recorded
Feb 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Bonn
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Augsburg, Germany , Berlin, Germany , Bielefeld, Germany , Bonn, Germany , Braunschweig, Germany , Bremen, Germany , Cologne, Germany , Cottbus, Germany , Datteln, Germany and 42 more locations